Mar 4, 2026 3-5pm ET
Wednesday on The Robert Scott Bell Show:
Hour 1
Trump Officials’ Ties to Bayer, Supreme Court Set to Wipe Out Glyphosate Cancer Claims The U.S. Supreme Court is poised to hear arguments in a case that could effectively eliminate most remaining cancer claims against Bayer/Monsanto over glyphosate-based herbicides like Roundup, following a series of appellate rulings that have narrowed plaintiff victories and a favorable legal landscape shaped by Trump-appointed justices and administration officials with documented ties to Bayer and the agricultural chemical industry. The case stems from thousands of lawsuits alleging that exposure to glyphosate caused non-Hodgkin lymphoma and other cancers, with juries in California and elsewhere awarding multimillion-dollar verdicts—including punitive damages—based on evidence that the company knew of risks but failed to warn consumers, yet most awards have been reduced or overturned on appeal due to judicial interpretations limiting punitive damages and causation standards. The Supreme Court petition seeks to resolve circuit splits on whether federal pesticide labeling law preempts state failure-to-warn claims and whether plaintiffs can rely on the International Agency for Research on Cancer’s “probably carcinogenic” classification when the EPA maintains glyphosate is not likely carcinogenic under typical use conditions. The article highlights connections between Bayer and key figures in the Trump administration: former EPA Administrator Andrew Wheeler, who previously lobbied for industry clients including pesticide manufacturers; current officials with prior Bayer/Monsanto employment or consulting roles; and judicial appointments seen as sympathetic to corporate interests, including Justices Gorsuch, Kavanaugh, and Barrett, whose records favor preemption doctrines and limits on mass tort liability. Children’s Health Defense and allied groups argue these ties create conflicts of interest that undermine impartial adjudication, while Bayer maintains the science supports safety and that litigation represents baseless claims exploiting judicial sympathy rather than evidence. The piece warns that a favorable ruling for Bayer could set precedent shielding pesticide makers from state tort liability nationwide, potentially extinguishing tens of thousands of pending claims and discouraging future accountability for alleged corporate misconduct in concealing health risks. It notes that despite billions paid in settlements—over $11 billion to date—Bayer continues to sell glyphosate products globally and maintains the chemical is safe when used as directed, while critics point to independent studies showing genotoxicity, endocrine disruption, and microbiome alterations at exposure levels below regulatory limits. The article frames the impending decision as a critical juncture in the intersection of corporate influence, federal preemption, and public health justice, with implications for the broader fight over chemical safety regulation and corporate liability in the face of mounting evidence of environmental and human harm from persistent herbicides.
Autism researchers form independent committee as counter to Kennedy-appointed group A group of autism researchers, former federal officials, and advocacy leaders announced the formation of the Independent Autism Coordinating Committee on March 3, 2026, as a direct response to Health and Human Services Secretary Robert F. Kennedy Jr.’s overhaul of the federal Interagency Autism Coordinating Committee (IACC), which he remade in January 2026 by appointing 21 new members, many with ties to organizations promoting the debunked claim that vaccines cause autism and endorsing unproven or potentially harmful treatments such as chelation therapy. The independent committee, comprising former IACC members, past directors of National Institutes of Health institutes including the National Institute of Mental Health, prominent autism scientists, and advocates such as Alison Singer of the Autism Science Foundation, aims to develop a science-based strategic plan for autism research priorities, coordinate efforts among nongovernmental funders, and ensure continued progress in evidence-based discovery and improved care for people with autism spectrum disorder. The group plans to operate similarly to the federal IACC by holding regular meetings, issuing recommendations, and addressing concerns about the resurgence of non-evidence-based approaches, with its first meeting scheduled for March 19, 2026. Singer stated the independent body was necessary because “we needed to take real action to ensure continued progress in autism science,” emphasizing collaboration among nongovernmental funders to shape research not reliant on federal dollars, which account for approximately $2 billion annually in autism-related funding. The federal IACC, established in 2006 under the Combating Autism Act and reauthorized through the Autism CARES Act, traditionally includes autistic self-advocates, parents, researchers, clinicians, and government representatives to advise on research strategies, service needs, and policy. Kennedy’s appointments drew sharp criticism from autism experts and former members for lacking representation from mainstream scientific leaders and disproportionately including individuals sympathetic to vaccine-autism theories rejected by extensive epidemiological evidence. Helen Tager-Flusberg of Boston University and founder of the Coalition of Autism Scientists described the new federal committee as a “radical departure” from past rosters and antithetical to evidence-based policy. The independent committee’s formation reflects broader efforts by medical and scientific communities to counter perceived ideological shifts in federal autism policy under Kennedy, who has long linked vaccines to autism despite scientific consensus finding no causal connection. Implications include potential bifurcation of research agendas, with nongovernmental funders possibly redirecting resources away from federal priorities if the official committee promotes non-evidence-based directions, while maintaining focus on rigorous science, improved diagnostics, interventions, and support services. The move underscores ongoing tensions between established autism research communities and the current administration’s emphasis on reevaluating environmental and medical factors in autism etiology.
Trump Signed a Directive to Accelerate Gain-of-Function Research President Donald Trump signed a classified national security directive in late February 2026 that directs federal agencies to accelerate research into gain-of-function experiments on potential pandemic pathogens, including coronaviruses, influenza strains, and select bacterial agents, reversing the informal moratorium and policy restrictions imposed during his first term and continued under subsequent administrations until recent changes. The directive, details of which have been partially disclosed through leaks and congressional briefings, instructs the Department of Health and Human Services, Department of Defense, and intelligence community to prioritize high-containment laboratory work aimed at understanding viral evolution, transmissibility enhancement, and host adaptation mechanisms in order to inform rapid countermeasure development, including vaccines, antivirals, and diagnostics for future biological threats. It allocates additional funding through existing biosecurity budgets and authorizes expanded collaboration with domestic academic institutions and select foreign partners under strict biosafety level 4 protocols, while establishing a new interagency review board to oversee proposals previously restricted under the P3CO framework. Proponents within the administration argue the research is essential for proactive defense against engineered or naturally emerging pathogens, citing intelligence assessments of ongoing gain-of-function activities in adversarial nations and the need to maintain U.S. leadership in biodefense technology. The move has drawn sharp criticism from biosafety experts, independent scientists, and some congressional Republicans who warn that resuming such experiments—particularly after the Covid-19 pandemic’s unresolved origins debate—heightens the risk of laboratory leaks, accidental release, or misuse, with historical incidents at U.S. facilities involving mishandled select agents underscoring persistent safety gaps even in high-containment settings. Critics note the irony of accelerating this work under an administration that previously criticized gain-of-function funding and promised greater transparency, arguing the directive lacks sufficient public oversight, independent risk assessment, or mandatory pause mechanisms for projects deemed excessively hazardous. The article frames the decision as a strategic pivot toward offensive biodefense capabilities amid rising geopolitical tensions, but warns that it could undermine public trust in federal science policy and reignite debates over dual-use research of concern. No official White House statement has confirmed the directive’s full scope or implementation timeline, though sources indicate initial projects may begin within months at existing BSL-4 laboratories. The development coincides with broader HHS and NIH policy shifts under Secretary Robert F. Kennedy Jr. and Director Jay Bhattacharya, who have publicly opposed certain gain-of-function work but appear to have acquiesced to national security priorities in this instance. Question of The Day!
Hi Robert,
I have a question please. My son had COVID. He was drinking in front of me, had a coughing fit, and spit some liquid from his mouth onto my face and a few drops into my eye. The next day, my eye was very irritated, and I started using Argentyn23. How many days do you think I should use it? Today is the third day, and it’s already getting better. Do you think this problem could be related to my son’s illness, or is it just a coincidence?
Best regards
Mercedes
Hour 2
Secret food additives: An investigation into what’s really in your food A months-long CNN investigation has uncovered that thousands of food additives—ranging from synthetic preservatives, artificial colors, flavor enhancers, emulsifiers, and processing aids—are currently allowed in U.S. foods under the FDA’s Generally Recognized as Safe (GRAS) self-determination pathway, where companies can independently declare ingredients safe without mandatory FDA review, notification, or public disclosure of safety data, resulting in an opaque system that obscures the full scope of what Americans consume daily. The probe identified over 10,000 substances with GRAS status, many undisclosed to the public or even to regulators, including novel nanomaterials, genetically engineered enzymes, and chemical derivatives introduced through proprietary formulations that food manufacturers classify as trade secrets. Experts interviewed, including former FDA officials and toxicologists, criticized the GRAS loophole—expanded in the 1997 regulation—as a regulatory failure that shifted responsibility from government oversight to industry self-regulation, allowing potentially harmful additives to enter the food supply without independent verification. Examples include high-dose synthetic antioxidants like BHA and BHT linked to endocrine disruption in animal studies, certain emulsifiers associated with gut microbiome alterations and inflammation, and artificial sweeteners with debated metabolic impacts, all permitted under GRAS despite ongoing scientific debate and calls for reevaluation. The investigation revealed that the FDA has affirmed GRAS status for only a small fraction of these substances through formal petitions, while the vast majority rely on company self-assessments often conducted by panels with industry ties, creating inherent conflicts of interest. Consumer advocates and public health researchers argue this secrecy violates the principle of informed choice, as labels rarely disclose these additives beyond vague terms like “natural flavors” or “artificial colors,” leaving shoppers unable to avoid potentially problematic ingredients. The report notes that while the FDA maintains GRAS substances are safe based on historical use or scientific consensus, critics point to emerging evidence of cumulative low-dose effects, synergistic interactions among multiple additives, and long-term risks not captured in initial assessments conducted decades ago. In response to mounting pressure—including petitions from public interest groups and bipartisan congressional calls for reform—the FDA announced in early 2026 plans to explore rulemaking that could require notification for new GRAS self-determinations and increase transparency, though no timeline or final proposal has been set. The investigation underscores broader concerns about the U.S. food regulatory framework, where speed to market and industry innovation often take precedence over precautionary evaluation, potentially contributing to rising rates of chronic conditions like obesity, metabolic syndrome, and autoimmune disorders linked to dietary factors. Health experts recommend consumers prioritize whole, minimally processed foods and scrutinize ingredient lists, while advocating for systemic changes to restore independent oversight and public access to safety data on all food additives.
Arizona Senate Advances Bill Requiring Parental Consent for COVID-19 Vaccination of Minors The Arizona Senate Health and Human Services Committee advanced Senate Bill 1491 on February 26, 2026, in a 5-3 party-line vote, with the legislation now heading to the full Senate for consideration; if enacted, the bill would prohibit healthcare providers from administering any COVID-19 vaccine to minors under 18 years of age without explicit written parental or legal guardian consent, overriding current state law that allows minors 12 and older to consent independently to certain vaccinations including COVID-19 shots under emergency use or full approval status. The measure, sponsored by Sen. Janae Shamp (R-Dist. 29) and co-sponsored by several Republican colleagues, explicitly targets COVID-19 vaccines while leaving other routine childhood immunizations unaffected, citing concerns over long-term safety data, potential adverse events including myocarditis in adolescent males, and the fundamental right of parents to make medical decisions for their children absent imminent danger to life or health. Supporters argue the bill restores parental authority eroded by pandemic-era policies that expanded minor consent rights, emphasizing that COVID-19 poses low risk of severe outcomes in healthy children and adolescents while vaccines carry documented risks that warrant heightened scrutiny and family involvement. Opponents, including Democratic committee members and public health advocates, contend the legislation undermines public health efforts to achieve high vaccination coverage necessary for community protection, could reduce uptake among minors in households with vaccine-hesitant parents, and sets a dangerous precedent for politicizing evidence-based immunization recommendations. The bill includes an emergency clause for immediate effect upon gubernatorial signature and provides exemptions only for medical contraindications documented by a licensed physician, with no provision for religious or philosophical exemptions to the consent requirement. Debate during committee highlighted conflicting interpretations of minor consent laws: proponents asserted that COVID-19 vaccines, unlike treatments for sexually transmitted infections or substance abuse, do not fall under established categories justifying independent minor decision-making, while opponents maintained that existing statutes already allow minors 12+ to consent to preventive immunizations and that overriding this authority could delay protection in outbreak scenarios. The legislation aligns with similar parental consent bills advancing in other Republican-led states amid national reevaluation of COVID-19 vaccination policies under the current administration, including narrowed federal recommendations and scrutiny of pediatric use. If passed by the full Senate and House and signed by Gov. Katie Hobbs, who has previously vetoed vaccine-related restrictions, the bill could face a veto or legal challenge on grounds of conflicting with federal emergency use authorization frameworks or state public health authority. The article frames SB 1491 as part of a broader push to reassert parental rights in medical decision-making for minors following perceived overreach during the pandemic, while noting potential impacts on school-based vaccination clinics, adolescent uptake rates, and ongoing public health efforts to maintain herd immunity against evolving SARS-CoV-2 variants.
BREAKING: Study Finds Living Near a Cell Tower Linked to Increased Cancer Risk A comprehensive epidemiological study published in Environmental Research examined cancer incidence among 1.2 million residents living within 500 meters of cell towers across 12 major U.S. metropolitan areas over 15 years and identified a statistically significant increase in overall cancer risk, with the strongest associations observed for brain tumors (odds ratio 1.68, 95% confidence interval 1.42–1.99), salivary gland cancers (OR 1.54, 95% CI 1.21–1.96), and hematologic malignancies including leukemia and lymphoma (OR 1.39, 95% CI 1.18–1.64) among individuals residing closest to towers compared to those living more than 2 kilometers away, after adjustment for age, sex, socioeconomic status, smoking history, and urban environmental confounders. The research utilized residential geocoding linked to FCC Antenna Structure Registration database tower locations and state cancer registry records, demonstrating a clear dose-response relationship where risk rose with decreasing distance and increasing cumulative radiofrequency exposure estimated from tower power output, antenna characteristics, and operational duration. Brain cancer risk was notably elevated in children and young adults under 30 (OR 2.12, 95% CI 1.58–2.84), while adult salivary gland tumors showed stronger associations in long-term residents (over 10 years) near high-power installations. The investigators highlighted that radiofrequency electromagnetic fields from cell towers operate in the non-ionizing range, yet chronic low-level exposure may trigger biological effects through non-thermal mechanisms such as oxidative stress via reactive oxygen species generation, DNA strand breaks, altered calcium signaling, disrupted melatonin production, and interference with cellular repair processes, consistent with limited animal and in vitro studies showing genotoxicity and tumor promotion at comparable exposure levels. While the International Agency for Research on Cancer classifies radiofrequency fields as possibly carcinogenic to humans (Group 2B) based mainly on heavy mobile phone use data, this study provides some of the most robust residential exposure evidence to date linking ambient tower emissions to cancer outcomes. Limitations include potential residual confounding from unmeasured variables such as personal device use or occupational exposures, reliance on ecological rather than individual dosimetry for exposure estimation, and the observational design that precludes definitive causation. The authors recommend precautionary measures including increased setback distances for new tower installations, stricter power density limits in residential zones, enhanced chronic low-level radiofrequency monitoring, and expanded epidemiological research to clarify exposure thresholds and long-term risks. The findings have intensified debate over the safety of existing 4G infrastructure and the ongoing 5G rollout, with public health advocates pushing for moratoriums on new towers near schools, hospitals, and high-density housing until more conclusive human data are available, while industry groups maintain that emissions remain well below FCC safety guidelines and no consistent evidence demonstrates harm at regulated levels. The study contributes to a growing body of research questioning assumptions that only thermal effects pose risk, underscoring the need for updated exposure standards that incorporate chronic, cumulative, and non-thermal biological impacts in densely populated environments.
COVID Justice COVID Justice is a nonprofit advocacy organization dedicated to seeking accountability, justice, and reparations for individuals and families harmed by COVID-19 policies, mandates, experimental medical interventions, and related government and institutional actions during the pandemic, with a primary focus on alleged vaccine injuries, coerced vaccination, medical discrimination, loss of livelihood, and violations of bodily autonomy and informed consent rights. The website serves as a central hub for affected persons to document their experiences, connect with legal resources, join support networks, and participate in collective efforts to pursue redress through litigation, legislation, and public awareness campaigns. Key initiatives include the COVID Justice Database, an open repository where survivors and families can submit detailed accounts of adverse events, discrimination, or rights violations linked to COVID measures, with thousands of entries already cataloged to build a comprehensive record of harm patterns across demographics, geographic regions, and specific interventions such as mRNA vaccines, lockdowns, mask mandates, and workplace requirements. The organization partners with attorneys specializing in vaccine injury, civil rights, employment discrimination, and constitutional law to provide free legal consultations, assist with filing claims under existing compensation programs like the Countermeasures Injury Compensation Program (CICP), and support class-action or multidistrict litigation against government entities, pharmaceutical companies, employers, and healthcare providers alleged to have engaged in coercive or fraudulent conduct. COVID Justice also advocates for legislative reforms including repeal of liability protections under the PREP Act and 1986 National Childhood Vaccine Injury Act, establishment of a dedicated vaccine injury compensation fund with less restrictive causation standards, and prohibition of future medical mandates without rigorous independent safety review and genuine informed consent processes. The site features survivor stories, expert commentary from physicians and scientists critical of pandemic policies, updates on pending lawsuits, petitions, and calls to action such as contacting lawmakers to support bills addressing vaccine injury transparency and accountability. It emphasizes that the organization’s mission is nonpartisan, focused on universal human rights principles rather than political affiliation, and committed to amplifying voices of the vaccine-injured, bereaved families, and those who lost careers, education, or freedoms due to COVID-era measures. Resources include guides on navigating VAERS reporting, accessing medical records, documenting injuries, and connecting with peer support groups, alongside a blog and newsletter tracking legal developments, policy changes, and grassroots organizing efforts aimed at preventing recurrence of similar policies in future health emergencies. The website positions itself as a counterweight to mainstream narratives that minimize or dismiss vaccine-related harms, seeking to restore public trust through transparency, independent investigation, and systemic reform that prioritizes individual rights and medical freedom over centralized public health mandates.Remember Friends, The Power to Heal is Yours!
